| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Prelude Therapeutics Inc | Chief Scientific Officer | Employee Stock Option (right to buy) | 150K | Mar 1, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| PRLD | Prelude Therapeutics Inc | Mar 1, 2024 | 1 | $0 | 4 | Mar 4, 2024 | Chief Scientific Officer |
| PRLD | Prelude Therapeutics Inc | Feb 7, 2023 | 1 | $0 | 4 | Feb 9, 2023 | Chief Scientific Officer |
| PRLD | Prelude Therapeutics Inc | Feb 15, 2022 | 1 | $0 | 4 | Feb 17, 2022 | Chief Scientific Officer |
| PRLD | Prelude Therapeutics Inc | Aug 26, 2021 | 8 | -$265K | 4 | Aug 30, 2021 | Chief Scientific Officer |
| PRLD | Prelude Therapeutics Inc | Aug 13, 2021 | 5 | -$76.6K | 4 | Aug 17, 2021 | Chief Scientific Officer |
| PRLD | Prelude Therapeutics Inc | Jul 27, 2021 | 4 | -$681K | 4 | Jul 29, 2021 | Chief Scientific Officer |
| PRLD | Prelude Therapeutics Inc | Jul 20, 2021 | 1 | $0 | 4 | Jul 22, 2021 | Chief Scientific Officer |
| PRLD | Prelude Therapeutics Inc | May 7, 2021 | 5 | -$394K | 4 | May 11, 2021 | Chief Scientific Officer |